Cargando…

Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels

Glycogen storage disease type 1a (GSD Ia) is an inborn error of metabolism caused by mutations in the G6PC gene, encoding the catalytic subunit of glucose-6-phosphatase. Early symptoms include severe fasting intolerance, failure to thrive and hepatomegaly, biochemically associated with nonketotic hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saeed, Ali, Hoogerland, Joanne A, Wessel, Hanna, Heegsma, Janette, Derks, Terry G J, van der Veer, Eveline, Mithieux, Gilles, Rajas, Fabienne, Oosterveer, Maaike H, Faber, Klaas Nico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	General Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001719/ https://www.ncbi.nlm.nih.gov/pubmed/31813960 http://dx.doi.org/10.1093/hmg/ddz283

Ejemplares similares

Next-generation glycogen storage diseases
por: Derks, Terry G. J., et al.
Publicado: (2018)

Impaired Very‐Low‐Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia
por: Hoogerland, Joanne A., et al.
Publicado: (2021)

Plasma Levels of Retinol Binding Protein 4 Relate to Large VLDL and Small LDL Particles in Subjects with and without Type 2 Diabetes
por: Wessel, Hanna, et al.
Publicado: (2019)

Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a
por: Lei, Yu, et al.
Publicado: (2020)

Increased atherosclerosis in a mouse model of glycogen storage disease type 1a
por: La Rose, Anouk M., et al.
Publicado: (2022)

Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
por: Peeks, Fabian, et al.
Publicado: (2017)

Hepatic stress associated with pathologies characterized by disturbed glucose production
por: Gjorgjieva, Monika, et al.
Publicado: (2019)

Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
por: Rutten, Martijn G. S., et al.
Publicado: (2023)

A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
por: Rossi, Alessandro, et al.
Publicado: (2022)

Cellular and metabolic effects of renin-angiotensin system blockade on glycogen storage disease type I nephropathy
por: Monteillet, Laure, et al.
Publicado: (2021)

Inhibition of Glycogen Synthase II with RNAi Prevents Liver Injury in Mouse Models of Glycogen Storage Diseases
por: Pursell, Natalie, et al.
Publicado: (2018)

Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia
por: La Rose, Anouk M., et al.
Publicado: (2021)

Pathogenesis of Hepatic Tumors following Gene Therapy in Murine and Canine Models of Glycogen Storage Disease
por: Kang, Hye-Ri, et al.
Publicado: (2019)

Human FXR Regulates SHP Expression through Direct Binding to an LRH-1 Binding Site, Independent of an IR-1 and LRH-1
por: Hoeke, Martijn O., et al.
Publicado: (2014)

Farnesoid X receptor and bile acids regulate vitamin A storage
por: Saeed, Ali, et al.
Publicado: (2019)

A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management
por: Peeks, Fabian, et al.
Publicado: (2021)

Glucose-6 Phosphate, a Central Hub for Liver Carbohydrate Metabolism
por: Rajas, Fabienne, et al.
Publicado: (2019)

Growth differentiation factor 7 autocrine signaling promotes hepatic progenitor cell expansion in liver fibrosis
por: Kong, Defu, et al.
Publicado: (2023)

Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions
por: Derks, Terry G. J., et al.
Publicado: (2015)

Glucose‐6‐Phosphate Regulates Hepatic Bile Acid Synthesis in Mice
por: Hoogerland, Joanne A., et al.
Publicado: (2019)

High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia
por: Haring, Martijn P.D., et al.
Publicado: (2022)

Hibernator-Derived Cells Show Superior Protection and Survival in Hypothermia Compared to Non-Hibernator Cells
por: Hendriks, Koen D.W., et al.
Publicado: (2020)

Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR‐associated protein 9–Mediated Gene Editing
por: Rutten, Martijn G.S., et al.
Publicado: (2021)

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease
por: Cao, Jingsong, et al.
Publicado: (2021)

Glucotoxicity Induces Glucose-6-Phosphatase Catalytic Unit Expression by Acting on the Interaction of HIF-1α With CREB-Binding Protein
por: Gautier-Stein, Amandine, et al.
Publicado: (2012)

Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas
por: Moest, Wouter, et al.
Publicado: (2018)

The potential of dietary treatment in patients with glycogen storage disease type IV
por: Derks, Terry G. J., et al.
Publicado: (2020)

Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study
por: Grünert, Sarah C., et al.
Publicado: (2023)

Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes
por: Saeed, Ali, et al.
Publicado: (2020)

The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases
por: Heiner-Fokkema, M. Rebecca, et al.
Publicado: (2020)

Simultaneous Induction of Glycolysis and Oxidative Phosphorylation during Activation of Hepatic Stellate Cells Reveals Novel Mitochondrial Targets to Treat Liver Fibrosis
por: Smith-Cortinez, Natalia, et al.
Publicado: (2020)

Lysosomal glycogen accumulation in Pompe disease results in disturbed cytoplasmic glycogen metabolism
por: Canibano‐Fraile, Rodrigo, et al.
Publicado: (2022)

Towards values‐based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders
por: Venema, Annieke, et al.
Publicado: (2022)

G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a
por: Roseman, Daniel S., et al.
Publicado: (2018)

Glycogen storage diseases: An update
por: Gümüş, Ersin, et al.
Publicado: (2023)

Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome
por: Sentner, Christiaan P., et al.
Publicado: (2016)

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs
por: Derks, Terry G. J., et al.
Publicado: (2021)

Intracellular lipids are an independent cause of liver injury and chronic kidney disease in non alcoholic fatty liver disease-like context
por: Monteillet, Laure, et al.
Publicado: (2018)

Biomarkers in Glycogen Storage Diseases: An Update
por: Molares-Vila, Alberto, et al.
Publicado: (2021)

Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib
por: Grünert, Sarah C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3c2v2fe8jr07m4d7oih2qgf3qm